Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ludovic Melly is active.

Publication


Featured researches published by Ludovic Melly.


Journal of Cardiothoracic Surgery | 2012

A new cable-tie based sternal closure system: description of the device, technique of implantation and first clinical evaluation

Martin Grapow; Ludovic Melly; Friedrich S. Eckstein; Oliver Reuthebuch

BackgroundWire closure still remains the preferred technique despite reasonable disadvantages. Associated complications, such as infection and sternal instability, cause time- and cost-consuming therapies. We present a new tool for sternal closure with its first clinical experience and results.MethodsThe sternal ZipFixTM System is based on the cable-tie principle. It primarily consists of biocompatible Poly-Ether-Ether-Ketone implants and is predominantly used peristernally through the intercostal space. The system provides a large implant-to-bone contact for better force distribution and for avoiding bone cut through.Results50 patients were closed with the ZipFixTM system. No sternal instability was observed at 30 days. Two patients developed a mediastinitis that necessitated the removal of the device; however, the ZipFixTM were intact and the sternum remained stable.ConclusionsIn our initial evaluation, the short-term results have shown that the sternal ZipFixTM can be used safely and effectively. It is fast, easy to use and serves as a potential alternative for traditional wire closure.


Human Gene Therapy Methods | 2012

Controlled Angiogenesis in the Heart by Cell-Based Expression of Specific Vascular Endothelial Growth Factor Levels

Ludovic Melly; Anna Marsano; Aurélien Frobert; Stefano Boccardo; Uta Helmrich; Michael Heberer; Friedrich S. Eckstein; Thierry Carrel; Marie-Noëlle Giraud; Hendrik T. Tevaearai; Andrea Banfi

Vascular endothelial growth factor (VEGF) can induce normal angiogenesis or the growth of angioma-like vascular tumors depending on the amount secreted by each producing cell because it remains localized in the microenvironment. In order to control the distribution of VEGF expression levels in vivo, we recently developed a high-throughput fluorescence-activated cell sorting (FACS)-based technique to rapidly purify transduced progenitors that homogeneously express a specific VEGF dose from a heterogeneous primary population. Here we tested the hypothesis that cell-based delivery of a controlled VEGF level could induce normal angiogenesis in the heart, while preventing the development of angiomas. Freshly isolated human adipose tissue-derived stem cells (ASC) were transduced with retroviral vectors expressing either rat VEGF linked to a FACS-quantifiable cell-surface marker (a truncated form of CD8) or CD8 alone as control (CTR). VEGF-expressing cells were FACS-purified to generate populations producing either a specific VEGF level (SPEC) or uncontrolled heterogeneous levels (ALL). Fifteen nude rats underwent intramyocardial injection of 10(7) cells. Histology was performed after 4 weeks. Both the SPEC and ALL cells produced a similar total amount of VEGF, and both cell types induced a 50%-60% increase in both total and perfused vessel density compared to CTR cells, despite very limited stable engraftment. However, homogeneous VEGF expression by SPEC cells induced only normal and stable angiogenesis. Conversely, heterogeneous expression of a similar total amount by the ALL cells caused the growth of numerous angioma-like structures. These results suggest that controlled VEGF delivery by FACS-purified ASC may be a promising strategy to achieve safe therapeutic angiogenesis in the heart.


Biotechnology and Bioengineering | 2016

Three dimensional multi‐cellular muscle‐like tissue engineering in perfusion‐based bioreactors

Giulia Cerino; Emanuele Gaudiello; Thomas Grussenmeyer; Ludovic Melly; Diana Nada Caterina Massai; Andrea Banfi; Ivan Martin; Friedrich Eckstein; Martin T. R. Grapow; Anna Marsano

Conventional tissue engineering strategies often rely on the use of a single progenitor cell source to engineer in vitro biological models; however, multi‐cellular environments can better resemble the complexity of native tissues. Previous described co‐culture models used skeletal myoblasts, as parenchymal cell source, and mesenchymal or endothelial cells, as stromal component. Here, we propose instead the use of adipose tissue‐derived stromal vascular fraction cells, which include both mesenchymal and endothelial cells, to better resemble the native stroma. Percentage of serum supplementation is one of the crucial parameters to steer skeletal myoblasts toward either proliferation (20%) or differentiation (5%) in two‐dimensional culture conditions. On the contrary, three‐dimensional (3D) skeletal myoblast culture often simply adopts the serum content used in monolayer, without taking into account the new cell environment. When considering 3D cultures of mm‐thick engineered tissues, homogeneous and sufficient oxygen supply is paramount to avoid formation of necrotic cores. Perfusion‐based bioreactor culture can significantly improve the oxygen access to the cells, enhancing the viability and the contractility of the engineered tissues. In this study, we first investigated the influence of different serum supplementations on the skeletal myoblast ability to proliferate and differentiate during 3D perfusion‐based culture. We tested percentages of serum promoting monolayer skeletal myoblast‐proliferation (20%) and differentiation (5%) and suitable for stromal cell culture (10%) with a view to identify the most suitable condition for the subsequent co‐culture. The 10% serum medium composition resulted in the highest number of mature myotubes and construct functionality. Co‐culture with stromal vascular fraction cells at 10% serum also supported the skeletal myoblast differentiation and maturation, hence providing a functional engineered 3D muscle model that resembles the native multi‐cellular environment. Biotechnol. Bioeng. 2016;113: 226–236.


Interactive Cardiovascular and Thoracic Surgery | 2013

A new cable-tie-based sternal closure device: infectious considerations

Ludovic Melly; Brigitta Gahl; Ruth Meinke; Florian Rueter; Peter Matt; Oliver Reuthebuch; Friedrich S. Eckstein; Martin Grapow

OBJECTIVES To determine the difference in sternal infection and other infectious events between conventional wire and cable-tie-based closure techniques post-sternotomy in a collective of patients after cardiac surgery. METHODS The sternal ZipFix™ (ZF) system consists of a biocompatible poly-ether-ether-ketone (PEEK) cable-tie that surrounds the sternum through the intercostal space and provides a large implant-to-bone contact. Between 1 February 2011 and 31 January 2012, 680 cardiac operations were performed via sternotomy at our institution. After the exclusion of operations for active endocarditis and early mortality within 7 days, 95 patients were exclusively closed with ZF and could be compared with 498 who were closed with conventional wires (CWs) during the same period. A multivariable logistic regression analysis, including body mass index, renal impairment and emergency as suspected confounders and inverse propensity weights was performed on the infection rate. RESULTS Total infection rate was 6.1%, with a total of 36 diagnosed sternal infections (5 in ZF and 31 in CW). Comparing ZF with CW with regard to sternal infection, there is no statistically significant difference related to the device (odds ratio: 0.067, confidence interval: 0.04-9.16, P=0.72). The propensity modelling provided excellent overlap and the mean propensity was almost the same in both groups. Thus, we have observed no difference in receiving either ZF or CW. No sternal instability was observed with the ZF device, unlike 4/31 patients in the CW group. The overall operation time is reduced by 11 min in the ZF group with identical perfusion and clamping times. CONCLUSIONS Our study underlines a neutral effect of the sternal ZipFix™ system in patients regarding sternal infection. Postoperative complications are similar in both sternal closure methods. The cable-tie-based system is fast, easy to use, reliable and safe.


Acta Biomaterialia | 2016

Engineered mesenchymal cell-based patches as controlled VEGF delivery systems to induce extrinsic angiogenesis

Stefano Boccardo; Emanuele Gaudiello; Ludovic Melly; Giulia Cerino; Davide Ricci; Ivan Martin; Friedrich S. Eckstein; Andrea Banfi; Anna Marsano

UNLABELLED Therapeutic over-expression of Vascular Endothelial Growth Factor (VEGF) by transduced progenitors is a promising strategy to efficiently induce angiogenesis in ischemic tissues (e.g. limb muscle and myocardium), but tight control over the micro-environmental distribution of the dose is required to avoid induction of angioma-like tumors. Therapeutic VEGF release was achieved by purified transduced adipose mesenchymal stromal cells (ASC) that homogeneously produce specific VEGF levels, inducing only normal angiogenesis after injection in non-ischemic tissues. However, the therapeutic potential of this approach mostly in the cardiac field is limited by the poor cell survival and the restricted area of effect confined to the cell-injection site. The implantation of cells previously organized in vitro in 3D engineered tissues could overcome these issues. Here we hypothesized that collagen sponge-based construct (patch), generated by ASC expressing controlled VEGF levels, can function as delivery device to induce angiogenesis in surrounding areas (extrinsic vascularization). A 7-mm-thick acellular collagen scaffold (empty), sutured beneath the patch, provided a controlled and reproducible model to clearly investigate the ongoing angiogenesis in subcutaneous mice pockets. VEGF-expressing ASC significantly increased the capillary in-growth inside both the patch itself and the empty scaffold compared to naïve cells, leading to significantly improved survival of implanted cells. These data suggest that this strategy confers control (i) on angiogenesis efficacy and safety by means of ASC expressing therapeutic VEGF levels and (ii) over the treated area through the specific localization in an engineered collagen sponge-based patch. STATEMENT OF SIGNIFICANCE Development of efficient pro-angiogenic therapies to restore the micro-vascularization in ischemic tissues is still an open issue. Although extensively investigated, the promising approach based on injections of progenitors transduced to over-express Vascular Endothelial Growth Factor (VEGF) has still several limitations: (i) need of a tight control over the microenvironmental VEGF dose to avoid angioma-like tumor growth; (ii) poor implanted cell survival; (iii) effect area restricted mainly to the injection sites. Here, we aimed to overcome these drawbacks by generating a novel cell-based controlled VEGF delivery device. In particular, transduced mesenchymal cells, purified to release a sustained, safe and efficient VEGF dose, were organized in three-dimensional engineered tissues to improve cell survival and provide a uniform vascularization throughout both the mm-thick implanted constructs themselves and the surrounding area.


Asian Cardiovascular and Thoracic Annals | 2011

Simplified closure of ministernotomy using thermoreactive sternal clips

Martin Grapow; Florian Rüter; Ludovic Melly; Bernhard Winkler; Friedrich S. Eckstein; Peter Matt

An increasing number of aortic valve replacements are performed through a ministernotomy. Due to the small incision and partial fixation of the caudal sternum, the traditional wire closure can be complicated and even harmful to the surrounding tissue. In such cases, we recommend the use of nitinol clips for sternal closure. This technique, which we have used in 48 patients, is simple, safe, and fast, and results in excellent outcomes.


Journal of Thoracic Disease | 2018

Fifty years of coronary artery bypass grafting

Ludovic Melly; Gianluca Torregrossa; Timothy Lee; Jean-Luc Jansens; John D. Puskas

Coronary artery bypass grafting (CABG) remains the most common cardiac surgery performed today worldwide. The history of this procedure can be traced back for more than 100 years, and its development has been touched by several pioneers in the field of cardiac surgery, who have contributed with both their successes and failures. With ever increasing follow up and number of patients treated, thinking regarding optimal CABG technique evolves continually. This article reviews the history of CABG from its early experimental work to recent technological advances.


Journal of Cellular and Molecular Medicine | 2018

Myocardial infarction stabilization by cell-based expression of controlled Vascular Endothelial Growth Factor levels

Ludovic Melly; Giulia Cerino; Aurélien Frobert; Stéphane Cook; Marie-Noëlle Giraud; Thierry Carrel; Hendrik T. Tevaearai Stahel; Friedrich S. Eckstein; Benoît Rondelet; Anna Marsano; Andrea Banfi

Vascular Endothelial Growth Factor (VEGF) can induce normal or aberrant angiogenesis depending on the amount secreted in the microenvironment around each cell. Towards a possible clinical translation, we developed a Fluorescence Activated Cell Sorting (FACS)‐based technique to rapidly purify transduced progenitors that homogeneously express a desired specific VEGF level from heterogeneous primary populations. Here, we sought to induce safe and functional angiogenesis in ischaemic myocardium by cell‐based expression of controlled VEGF levels. Human adipose stromal cells (ASC) were transduced with retroviral vectors and FACS purified to generate two populations producing similar total VEGF doses, but with different distributions: one with cells homogeneously producing a specific VEGF level (SPEC), and one with cells heterogeneously producing widespread VEGF levels (ALL), but with an average similar to that of the SPEC population. A total of 70 nude rats underwent myocardial infarction by coronary artery ligation and 2 weeks later VEGF‐expressing or control cells, or saline were injected at the infarction border. Four weeks later, ventricular ejection fraction was significantly worsened with all treatments except for SPEC cells. Further, only SPEC cells significantly increased the density of homogeneously normal and mature microvascular networks. This was accompanied by a positive remodelling effect, with significantly reduced fibrosis in the infarcted area. We conclude that controlled homogeneous VEGF delivery by FACS‐purified transduced ASC is a promising strategy to achieve safe and functional angiogenesis in myocardial ischaemia.


Journal of Tissue Engineering and Regenerative Medicine | 2014

Engineering of a contractile cardiac patch with an intrinsic vasculogenic potential

Giulia Cerino; Emanuele Gaudiello; Ludovic Melly; Thomas Grussenmeyer; Martin T. R. Grapow; Ivan Martin; Diana Nada Caterina Massai; Friedrich Eckstein; Andrea Banfi; A. Scherberich; Anna Marsano

Introduction: Decellularized engineered extracellular matrices (ECM) are used in a variety of regenerative medicine applications. Existing decellularization strategies rely on cell lysis and generally result in a variable but significant impairment of the ECM structure/composition. As an alternative, we aimed at activating the apoptotic pathway in order to decellularize engineered matrices while preserving their osteo-inductive properties [1]. Materials and methods: We generated a death-inducible, immortalized human Mesenchymal Stromal Cell (hMSC) line [2]. Cells were seeded on ceramic scaffolds and cultured for 4 weeks in osteogenic medium in a 3D perfusion bioreactor system (U-cup, Cellec). The ECM was decellularized by direct supply of the apoptotic inducer in the 3D culture system. Grafts were implanted in a rat cranial defect model to assess their regenerative potential after 12 weeks. Results: Cells were successfully seeded and differentiated, leading to deposition of a dense ECM during 3D culture. The apoptosis induction allowed for efficient decellularization while preserving the secreted matrix. These “apoptized” cell-free ECM coated constructs induced superior bone regeneration than control materials (Fig. 2). Areas of de novo bone formation not connected with surrounding bone suggest osteoinductive properties of the grafts.


Tissue Engineering Part C-methods | 2012

Generation of Human Adult Mesenchymal Stromal/Stem Cells Expressing Defined Xenogenic Vascular Endothelial Growth Factor Levels by Optimized Transduction and Flow Cytometry Purification

Uta Helmrich; Anna Marsano; Ludovic Melly; Thomas Wolff; Liliane Christ; Michael Heberer; Arnaud Scherberich; Ivan Martin; Andrea Banfi

Collaboration


Dive into the Ludovic Melly's collaboration.

Top Co-Authors

Avatar

Andrea Banfi

University Hospital of Basel

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anna Marsano

University Hospital of Basel

View shared research outputs
Top Co-Authors

Avatar

Emanuele Gaudiello

University Hospital of Basel

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jean-Luc Jansens

Free University of Brussels

View shared research outputs
Top Co-Authors

Avatar

Anna Marsano

University Hospital of Basel

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Friedrich Eckstein

University Hospital of Basel

View shared research outputs
Researchain Logo
Decentralizing Knowledge